News >

Real-World Data With Niraparib Show Lower AEs Vs ENGOT-OV6/NOVA Trial in Ovarian Cancer

Wayne Kuznar
Published: Thursday, Nov 08, 2018

Jack R. Gallagher, MSc

Jack R. Gallagher, MSc

Real-world incidences of nausea, thrombocytopenia, and fatigue were markedly lower in patients with platinum-sensitive, recurrent ovarian cancer receiving a starting 200-mg daily dose of niraparib (Zejula) versus those enrolled on the phase III ENGOT-OV6/NOVA trial, according to data presented at the 2018 ESMO Congress.1

The authors concluded that additional research is needed to further evaluate the effect of lower doses of niraparib than occurred in NOVA on frequency and severity of AE occurrence in real-world practice.

References

  1. Gallagher JR, Heap KJ, Carroll S. Real world occurrence of top three clinical-trial reported adverse events of PARP inhibitor niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer, a national retrospective observational study of a 200 mg/day starting-dose cohort. In: Proceedings from the 2018 ESMO Congress; October 19-23, 2018; Munich, Germany. Abstract 986P.
  2. Berek JS, Matulonis UA, Peen U, et al. Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018;29:1784-92. doi: 10.1093/annonc/mdy181.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: A Nurses' Guide to Managing Adverse Events Associated with PARP InhibitorsJun 30, 20201.0
Community Practice Connections™: Evolutions in the Treatment and Management of Advanced Cervical Cancer: Leveraging the Immunosuppressive Microenvironment, Addressing Ongoing Clinical NeedsJun 30, 20201.5
Publication Bottom Border
Border Publication
x